Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to determine whether a group format Community Reinforcement and Family Training (CRAFT) and Self-Directed CRAFT Delivery are more effective than non-intervention in terms of Concerned Significant Others (CSO) well- being and cost- effectiveness.


Clinical Trial Description

The aim of this study is to determine the applicability and effectiveness of (a) CRAFT group format in conjunction with the CRAFT self-help book and (b) a CRAFT self-help book (self-directed CRAFT delivery condition), compared to (c) non-intervention (control). The primary aim is increase CSO well- being and reduce CSO health complaints. CSOs will be assessed at baseline (T0), 2 months (end of intervention) (T1), 3 months- (T2), and 6 months follow-up (T3), independently of the assigned condition. Secondary outcomes will encompass cost-effectiveness of both CRAFT interventions. Also, we measure IP engagement and IPs' substance use.

Since the negative consequences of substance abuse are not limited to alcohol- and drug users themselves, it also affects the lives of family members and close friends (CSOs). This study focusses on CSOs to improve their lives. Recruitment will take place in the Netherlands (nation- wide). Assessment and the CRAFT group intervention will be conducted at six different locations (Arnhem, Doetinchem, Ede, Nijmegen, Tiel and Zevenaar, all in the province of Gelderland) in the Netherlands. Participants will be recruited via advertisements on the Internet, social media, websites of IrisZorg (centre for addiction care and sheltered housing ), and subsequently, in local newspapers and flyers located in emergency rooms, general practitioners, family practice clinics, and mental health based treatment agencies.

To obtain information about the presence of psychiatric disorders of the CSOs, a Dutch version of the Mini-International Neuropsychiatric Interview (M.I.N.I.) will be used. After initial assessment, a randomization procedure will be conducted by an independent researcher, who is affiliated to the Erasmus Medical Center, Rotterdam, the Netherlands. CSOs will be informed about the allocation of conditions within 1 week, after initial admission. Several outcome measures will be used in this study. The following will be measured:

1. CSO well- being (including physical and psychological health and complaints, quality of life, quality of the relationship, self- efficacy and social support);

2. cost-effectiveness of both CRAFT and Self- Directed Delivery compared to non- intervention.

3. IP engagement and IP substance use.

Using the primary outcome, CSO well-being, a priori power analysis is completed. Means and standard deviations for CSO well-being, measured with the Beck Depression Inventory (BDI), for Group CRAFT were used (Miller et al., 1999). An effect size was calculated (f = 0.22). The power analysis, conducted with the online program called G-power, indicated that a total sample size of 69 CSOs is needed to achieve a power of 95% for detecting a medium effect size when using the p = 0.05 criterion of statistical significance. These numbers are based on an ANOVA with a within-between subject design. Based on the pilot study of Kirby et al. (1999), 23% drop out after 3- and 6- month follow-up is taken into account. This means that, including the 23% drop-out-rate and based on the sample size of 69, an N of 85 is needed after 3 months and that a total N of 105 is needed to complete all assessments. Summarized, to be able to have at least 69 assessments completed at 6- month follow- up, a total sample size of 105 CSOs is required; with an estimated total drop-out rate of 34%. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02510508
Study type Interventional
Source IrisZorg
Contact
Status Terminated
Phase N/A
Start date August 2015
Completion date February 2017

See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A
Completed NCT02511886 - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder Phase 2
Active, not recruiting NCT02185131 - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. Phase 2